Pulmonx Co. (NASDAQ:LUNG) Receives Average Rating of “Moderate Buy” from Analysts

Pulmonx Co. (NASDAQ:LUNG) has been given an average rating of “Moderate Buy” by the six ratings firms that are presently covering the stock, Marketbeat.com reports. One research analyst has rated the stock with a hold rating and five have assigned a buy rating to the company. The average 1 year target price among brokers that have issued a report on the stock in the last year is $14.83.

Several equities research analysts have recently commented on the company. Canaccord Genuity Group upped their price objective on Pulmonx from $15.00 to $16.00 and gave the stock a “buy” rating in a research note on Thursday, August 1st. Wells Fargo & Company reduced their price target on Pulmonx from $14.00 to $10.00 and set an “equal weight” rating for the company in a research report on Thursday, August 1st. Finally, Lake Street Capital initiated coverage on Pulmonx in a research report on Tuesday, June 4th. They set a “buy” rating and a $12.00 price objective on the stock.

Pulmonx Price Performance

NASDAQ LUNG opened at $8.31 on Monday. The company has a 50-day moving average price of $7.07 and a 200-day moving average price of $7.63. Pulmonx has a 52 week low of $5.46 and a 52 week high of $14.84. The company has a quick ratio of 7.92, a current ratio of 8.97 and a debt-to-equity ratio of 0.37. The firm has a market capitalization of $322.56 million, a P/E ratio of -5.40 and a beta of 0.63.

Pulmonx (NASDAQ:LUNG) last announced its earnings results on Wednesday, July 31st. The company reported ($0.39) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.41) by $0.02. Pulmonx had a negative net margin of 75.56% and a negative return on equity of 50.79%. The company had revenue of $20.78 million during the quarter, compared to analyst estimates of $20.23 million. Equities research analysts anticipate that Pulmonx will post -1.64 earnings per share for the current year.

Insider Buying and Selling at Pulmonx

In other Pulmonx news, CEO Steven S. Williamson acquired 14,245 shares of the company’s stock in a transaction dated Tuesday, August 20th. The stock was purchased at an average price of $6.84 per share, with a total value of $97,435.80. Following the completion of the purchase, the chief executive officer now directly owns 219,531 shares in the company, valued at approximately $1,501,592.04. The acquisition was disclosed in a filing with the SEC, which can be accessed through this hyperlink. In related news, CEO Steven S. Williamson purchased 14,245 shares of Pulmonx stock in a transaction on Tuesday, August 20th. The shares were bought at an average cost of $6.84 per share, for a total transaction of $97,435.80. Following the acquisition, the chief executive officer now owns 219,531 shares in the company, valued at approximately $1,501,592.04. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Also, insider Geoffrey Beran Rose sold 4,586 shares of the stock in a transaction that occurred on Tuesday, September 3rd. The shares were sold at an average price of $6.70, for a total value of $30,726.20. Following the transaction, the insider now directly owns 295,433 shares of the company’s stock, valued at $1,979,401.10. The disclosure for this sale can be found here. Insiders have sold a total of 11,535 shares of company stock valued at $76,587 over the last ninety days. 5.70% of the stock is currently owned by company insiders.

Institutional Investors Weigh In On Pulmonx

A number of hedge funds have recently bought and sold shares of the business. Sei Investments Co. increased its holdings in shares of Pulmonx by 2.5% in the 1st quarter. Sei Investments Co. now owns 72,626 shares of the company’s stock worth $673,000 after buying an additional 1,800 shares during the last quarter. Dynamic Technology Lab Private Ltd bought a new stake in Pulmonx during the fourth quarter worth approximately $156,000. BNP PARIBAS ASSET MANAGEMENT Holding S.A. increased its stake in Pulmonx by 7.0% during the second quarter. BNP PARIBAS ASSET MANAGEMENT Holding S.A. now owns 1,059,018 shares of the company’s stock worth $6,714,000 after acquiring an additional 69,595 shares during the last quarter. Primecap Management Co. CA raised its position in Pulmonx by 2.2% during the fourth quarter. Primecap Management Co. CA now owns 5,646,451 shares of the company’s stock valued at $71,992,000 after purchasing an additional 124,050 shares during the period. Finally, Vanguard Group Inc. lifted its stake in shares of Pulmonx by 0.6% in the 1st quarter. Vanguard Group Inc. now owns 2,077,859 shares of the company’s stock valued at $19,262,000 after purchasing an additional 11,417 shares during the last quarter. Hedge funds and other institutional investors own 91.04% of the company’s stock.

About Pulmonx

Pulmonx Corporation, a commercial-stage medical technology company, provides minimally invasive devices for the treatment of chronic obstructive pulmonary diseases. The company offers Zephyr Endobronchial Valve, a solution for the treatment of patients with hyperinflation associated with severe emphysema; and Chartis Pulmonary Assessment System, a balloon catheter and console system with flow and pressure sensors that are used to assess the presence of collateral ventilation.